Condition: Multiple Myeloma (MM) · Plasma Cell Leukemia (PCL) · Sponsor: University of Leeds
iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others. Patients can take part if their doctor would otherwise recommend the standard NHS treatment daratumumab, lenalidomide and dexamethasone (DRd). After six months of DRd, the subsequent treatment a patient receives in iFIT is based on two factors: the patient's fitness level and treatment response. The trial compares different treatment strategies to determine whether outcomes can be improved for specific patient groups.
This description comes directly from the study's public registry record.
Emma McNaught · 0113 343 1978 · ctru-ifit@leeds.ac.uk
Catherine Olivier · ctru-ifit@leeds.ac.uk
Always discuss trial participation with your own doctor first.
| Bristol Haematology and Oncology Centre | Bristol, United Kingdom | Not Yet Recruiting |
| Eastbourne District General Hospital | Eastbourne, United Kingdom | Not Yet Recruiting |
| St James University Hospital | Leeds, United Kingdom | Not Yet Recruiting |
| The Clatterbridge Cancer Centre - Liverpool | Liverpool, United Kingdom | Recruiting |
| The Royal Marsden Hospital | London, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07649525